Case-Based Roundtable
General Dermatology
Eczema
Chronic Hand Eczema
Alopecia
Aesthetics
Vitiligo
COVID-19
Actinic Keratosis
Precision Medicine and Biologics
Rare Disease
Wound Care
Rosacea
Psoriasis
Psoriatic Arthritis
Atopic Dermatitis
Melasma
NP and PA
Skin Cancer
Hidradenitis Suppurativa
Drug Watch
Pigmentary Disorders
Acne
Pediatric Dermatology
Practice Management
Prurigo Nodularis
Buy-and-Bill

Plaque Psoriasis Management: Evaluating Non-Steroidal Treatments and Current Data Trends : Episode 7

Opinion

Video

July 18, 2024

TYK2 Inhibition and Deucravacitinib: Mechanism of Action, Safety Considerations, and Patient-Provider Conversations

Author(s):

Alexa Hetzel, MS, PA-C,Andrew Mastro, MS, PA-C

Key opinion leaders examine TYK2 inhibition and deucravacitinib, focusing on the mechanism of action, safety profile, and strategies for effective patient-provider communication regarding this treatment approach.

EP: 1.Navigating Plaque Psoriasis: Insights into the Psychosocial Impact and Evolving Treatment Landscape

EP: 2.Plaque Psoriasis Case Study: Patient Presentation, Treatment Selection, and Shared Decision-Making for Improved Outcomes

EP: 3.Empowering Patients with Plaque Psoriasis: Navigating Treatment Challenges Informed Patient Conversations and Decision Trees

EP: 4.A Conversation on Combination Therapy, Safety Profiles, and Targeted IL-17 Systemic Treatments

EP: 5.Clinical Insights: Managing Psoriasis Treatment Dynamics and Strategic Therapy Switching Considerations

EP: 6.Head-to-Head Clinical Trials: Comparing Psoriasis Treatment Response Rates

Now Viewing

TYK2 Inhibition and Deucravacitinib: Mechanism of Action, Safety Considerations, and Patient-Provider Conversations

EP: 1.Navigating Plaque Psoriasis: Insights into the Psychosocial Impact and Evolving Treatment Landscape

EP: 2.Plaque Psoriasis Case Study: Patient Presentation, Treatment Selection, and Shared Decision-Making for Improved Outcomes

EP: 3.Empowering Patients with Plaque Psoriasis: Navigating Treatment Challenges Informed Patient Conversations and Decision Trees

EP: 4.A Conversation on Combination Therapy, Safety Profiles, and Targeted IL-17 Systemic Treatments

EP: 5.Clinical Insights: Managing Psoriasis Treatment Dynamics and Strategic Therapy Switching Considerations

EP: 6.Head-to-Head Clinical Trials: Comparing Psoriasis Treatment Response Rates

EP: 7.TYK2 Inhibition and Deucravacitinib: Mechanism of Action, Safety Considerations, and Patient-Provider Conversations

EP: 8.Comparative Analysis: Deucravacitinib and Adalimumab in Psoriasis Treatment

EP: 9.Understanding IL-17 Therapies: Treatment Considerations, Rapid Response, and Impact on Plaque Psoriasis Location

EP: 10.Expert Insights into Managing Inadequate Response to Systemic Therapies: Strategies and Solutions

EP: 11.Long-Term Efficacy and Insights from POETYK PSO-1 Studies: Implications for Psoriasis Treatment

EP: 12.Achieving Durable Responses: Physician's Guide to Interpreting Long-Term Efficacy Data

EP: 13.When to Discontinue Treatment: Interpreting Safety Signals and Adverse Event Patterns

EP: 14.Updating Treatment Guidelines: Incorporating Novel Therapies to Address Unmet Needs

EP: 15.Available Psoriasis, Patient Involvement, and Holistic Treatment